advertisement
Abstract #27552 Published in IGR 12-4
Associations of polymorphisms in the ADRB1 and ADRB2 genes and response to timolol and betaxolol in glaucoma patients
Sabato M; Leffler C; Wilkinson D; Ferreira-Gonzalez AJournal of Molecular Diagnostics 2010; 12: 866
Introduction: The goal of glaucoma therapy is to preserve vision by lowering intraocular pressure (IOP). The ability to predict the effectiveness of glaucoma therapy might provide physicians with the means to more appropriately select the best medication for a given patient. We undertook a prospective clinical trial to evaluate the genetic association between polymorphisms in the ADRB1 and ADRB2 genes with response to topical treatment with timolol and betaxolol (beta-adrenergic receptor antagonists). Methods: The subject's population consisted of 57 patients in the Department of Ophthalmology at VCUHS who required treatment with an intraocular pressure lowering agent for glaucoma or ocular hypertension. After patient's granted written informed consent, they had a baseline visit and then, patients received 4 weeks of treatment with timolol 0.5% in both eyes twice daily, followed by a washed out period of 4 weeks with no medication and then, 4 weeks of treatment with betaxolol hydrochloride 0.25% in both eyes twice daily. Intraocular pressure, blood pressure and pulse were recorded at baseline and after 3, 4, 7, and 8 weeks of therapy. The test drug was administered by the physician 90 minutes before intraocular pressure measurement on the follow-up days. At the first follow-up visit, whole blood was taken to identify c.1165C>G (p.Arg389Gly) and c.145A>G (p.Ser49Gly) variants of the ADRB1 gene and c.46A>G (p.Arg16Gly) and c.79C>G (p.Gln27Glu) variants of the ADRB2 gene with the methods already described. Analysis of Variance was used to test for differences between the three genotypes for a particular variant. Results: We found an association between p.Arg16Arg and p.Gln27Glu genotypes in the ADRB2 gene and reduction in IOP following treatment with a topical B-blocker. Conclusions: Data from this cohort reinforces the need for a multisite study with a larger population of glaucoma patients.
M. Sabato. Virginia Commonwealth University Health System, RichmondUnited States.
Classification:
3.4.2 Gene studies (Part of: 3 Laboratory methods > 3.4 Molecular genetics)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)